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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERAtrial Fibrillation in Cancer Patients 945Dimitrios Farmakis, John Parissis, Gerasimos Filippatos
In this state-of-the-art paper, Farmakis and colleagues present the epidemiology and
pathophysiology of atrial ﬁbrillation (AF) in patients with cancer. Challenges speciﬁc to
treating AF in patients with malignancy are discussed, and treatment guidelines based on the
current evidence are presented.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYProcedural Volume and Radial Versus Femoral Access 954
Sanjit S. Jolly, John Cairns, Salim Yusuf, Kari Niemela, Philippe Gabriel Steg, Matthew Worthley,
Emile Ferrari, Warren J. Cantor, Anthony Fung, Nicholas Valettas, Michael Rokoss,
Goran K. Olivecrona, Petr Widimsky, Asim N. Cheema, Peggy Gao, Shamir R. Mehta,
for the RIVAL Investigators
The objective of this study was to evaluate the relationship between procedural volume
and outcomes with the radial and femoral approach in patients with acute coronary syndrome
undergoing coronary intervention. Pre-speciﬁed subgroup analysis was carried out in
patients enrolled in the RIVAL (RadIal Vs. FemorAL) trial. The analysis revealed that in
high-volume radial centers, the primary outcome (death, myocardial infarction, stroke, or
noncoronary bypass surgery-related major bleeding) was reduced with radial versus femoral
access (hazard ratio: 0.49), but not in intermediate- or low-volume centers. There was no
difference in primary outcome based on operator volume. Jolly and colleagues conclude that
procedural volume and expertise are important, particularly for radial percutaneous coronary
intervention.(continued on page A-20)
MARCH 18, 2014 (continued) A-20INTERVENTIONAL CARDIOLOGYThe STEMI-RADIAL Trial 964Ivo Bernat, David Horak, Josef Stasek, Martin Mates, Jan Pesek, Petr Ostadal, Vlado Hrabos,
Jaroslav Dusek, Jiri Koza, Zdenek Sembera, Miroslav Brtko, Ondrej Aschermann, Michal Smid,
Pavel Polansky, Abdul Al Mawiri, Jan Vojacek, Josef Bis, Olivier Costerousse, Olivier F. Bertrand,
Richard Rokyta
The STEMI-RADIAL (ST Elevation Myocardial Infarction treated by RADIAL or
femoral approach) trial compares the radial and femoral approach in patients presenting with
ST-segment elevation myocardial infarction (STEMI) and undergoing primary percutaneous
coronary intervention (PCI). A total of 707 patients were randomized, with one primary
endpoint of cumulative incidence of major bleeding and vascular access site complications at
30 days. The primary endpoint occurred in 1.4% in the radial group and 7.2% in the femoral
group (p ¼ 0.0001). Intensive care stay and contrast consumption were signiﬁcantly reduced
in the radial group. Mortality in the radial and femoral groups at 3 and 6 months were
similar. In patients with STEMI undergoing primary PCI, the radial approach was associated
with a signiﬁcantly lower incidence of major bleeding and access site complication and better
net clinical beneﬁt.
Editorial Comment: Robert J. Applegate, p. 973INTERVENTIONAL CARDIOLOGYUnderexpansion and Post-Dilation in Balloon-Expandable TAVR 976
Marco Barbanti, Jonathon Leipsic, Ronald Binder, Danny Dvir, John Tan, Melanie Freeman,
Bjarne Norgaard, Nicolaj Hansson, Anson Cheung, Jian Ye, Tae-Hyun Yang, Kasia Maryniak,
Rekha Raju, Angus Thompson, Philipp Blanke, Sandra Lauck, David Wood, John Webb
The objective of this study was to assess the clinical outcomes and hemodynamic performance
associated with a strategy of underexpanding balloon-expandable transcatheter heart valves
(THVs) when excessive oversizing was a concern. Patients (n ¼ 47) who underwent
transcatheter aortic valve replacement with an intentionally-underexpanded THV (balloon-
ﬁlled volume reduced by w10%) were compared with consecutive control patients who had
nominal THV balloon deployment (n ¼ 87). Echocardiographic THV area, gradient,
paravalvular regurgitation, and in-hospital outcomes were similar for both groups. This study
reveals that intentionally underexpanding balloon-expandable THVs by underﬁlling the
deployment balloon did not adversely affect procedural clinical outcomes, THV gradients,
or THV areas.(continued on page A-21)
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Dhanunjaya Lakkireddy, Yeruva Madhu Reddy, Luigi Di Biase, Ajay Vallakati, Moussa C. Mansour,
Pasquale Santangeli, Sandeep Gangireddy, Vijay Swarup, Fadi Chalhoub, Donita Atkins,
Sudharani Bommana, Atul Verma, Javier E. Sanchez, J. David Burkhardt, Conor D. Barrett,
Salwa Baheiry, Jeremy Ruskin, Vivek Reddy, Andrea Natale
The purpose of this study was to evaluate the feasibility and safety of uninterrupted
rivaroxaban during atrial ﬁbrillation (AF) ablation. A total of 642 patients from a prospective
registry of patients undergoing AF ablation were studied. Patients on uninterrupted
periprocedural rivaroxaban were matched with an equal number of patients on uninterrupted
warfarin therapy undergoing AF ablation at the same time. There were no differences in the
major bleeding complications (1.6% vs. 1.9%), minor bleeding complications (5.0% vs. 5.9%),
or embolic complications (1 [0.3%] vs. 1 [0.3%]) between the rivaroxaban and warfarin
groups, respectively, in the ﬁrst 30 days. Uninterrupted rivaroxaban therapy appears to be
equally as safe and efﬁcacious as uninterrupted warfarin in preventing bleeding and
thromboembolic events in patients undergoing AF ablation.CARDIAC IMAGINGCMR Plaque Imaging Predicts Coronary Events 989Teruo Noguchi, Tomohiro Kawasaki, Atsushi Tanaka, Satoshi Yasuda, Yoichi Goto, Masaharu Ishihara,
Kunihiro Nishimura, Yoshihiro Miyamoto, Koichi Node, Nobuhiko Koga
Coronary high-intensity plaques (HIPs), visualized by noncontrast T1-weighted imaging
(T1WI), are associated with characteristics of vulnerable plaques, including positive
remodeling, lower Hounsﬁeld units, and ultrasound attenuation. However, it is not known
whether the presence of HIPs is associated with an increased risk of coronary events. Signal
intensity of coronary plaques was determined in 568 patients with suspected or known
coronary artery disease (CAD) that underwent noncontrast T1WI to determine the plaque to
myocardial signal intensity ratio (PMR). The presence of PMR 1.4 plaques was a
signiﬁcant independent predictor of coronary events (hazard ratio [HR]: 3.96) compared
with the presence of CAD (HR: 3.56) and other traditional risk factors. Event-free survival
was lowest in the PMR 1.4 and CAD group and highest in the PMR <1.4 and no-CAD
group. HIPs identiﬁed in a noninvasive, quantitated manner are signiﬁcantly associated with
coronary events and, may thus, represent a novel predictive factor.
Editorial Comment: Paul Schoenhagen, Rene Botnar, p. 1000(continued on page A-22)
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Mark A. Hlatky, David Shilane, Rory Hachamovitch, Marcelo F. DiCarli, for the SPARC Investigators
This paper compares the economic outcomes of patients undergoing different noninvasive
tests to evaluate suspected coronary artery disease (CAD). The observational SPARC (Study
of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease)
registry of 1,703 patients who underwent coronary computed tomography angiography
(CTA), positron emission tomography (PET), or single-photon emission computed
tomography (SPECT) for the diagnosis of suspected CAD was analyzed. Two-year costs
were highest after PET ($6,647), intermediate after CTA ($4,909), and lowest after SPECT
($3,520). Two-year mortality was 0.7% after CTA, 1.6% after SPECT, and 5.5% after PET.
Hlatky and colleagues conclude that costs were signiﬁcantly lower after using SPECT rather
than CTA or PET in the evaluation of suspected CAD.
Editorial Comment: Todd C. Villines, James K. Min, p. 1009PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCHCardioprotective Effects of FLT3 1011
Otmar Pﬁster, Vera Lorenz, Angelos Oikonomopoulos, Lifen Xu, Stéphanie P. Häuselmann,
Christopher Mbah, Beat A. Kaufmann, Ronglih Liao, Aleksandra Wodnar-Filipowicz,
Gabriela M. Kuster
FMS-like tyrosine kinase 3 (FLT3) is a target of receptor tyrosine kinase inhibitors used for
anticancer therapy. The objective of this study was to better understand the roles of FLT3 in
the heart. Myocardial infarction was induced in mice. Cardiac analysis subsequently revealed
that intramyocardial injection of FL decreased infarct size and ameliorated post-myocardial
infarction remodeling and function. This beneﬁcial effect was associated with reduced
apoptosis, including myocytes in the border zone. Cardiomyocytes expressed functional
FLT3, and FLT3 messenger ribonucleic acid and protein were up-regulated under oxidative
stress, identifying cardiomyocytes as FL target cells. Pﬁster and colleagues conclude that
FLT3 is a cytoprotective system in the heart and a potential therapeutic target in ischemic
cardiac injury.
Editorial Comment: Ana Barac, p. 1020
